West Pharmaceutical Services Beats Estimates in Q2 CY2026, Guides for Strong Full-Year Sales
West Pharmaceutical Services reported strong Q2 CY2026 earnings that exceeded analysts' expectations, driven by double-digit sales and EPS growth. The company guided for strong full-year sales, driven by high-value biologics. West Pharmaceutical's Q2 adjusted EPS and revenue exceeded estimates, beating FactSet's predictions.
WST reported second-quarter CY2026 earnings that comfortably beat expectations, with double-digit sales and EPS growth. Adjusted EPS came in at $2.37 and revenue reached $872.3 million, both ahead of FactSet estimates.
Growth was led by demand for the company's high-value biologics components, the elastomer seals and drug-delivery systems used in injectable therapies, including the GLP-1 drug class. The strength prompted management to raise full-year sales guidance.
The beat signals a recovery in West's core proprietary-products segment after a stretch of customer destocking. Investors will watch whether high-value-product momentum and biologics demand can sustain the raised guidance through the back half of the year.
Related Stocks
Powered by SentiSense - Intelligent Market Analysis